Operating costs in H117 were largely in line with our expectations, while a one-off payment was a welcome resolution of Probiodrug’s long-outstanding potential tax liability. Following the overall positive Phase IIa data with PQ912 for Alzheimer’s disease (AD) released in June 2017, Probiodrug reiterated in its H117 report that all strategic options for further development are on the table. Depending on available funding, the company could initiate the next study looking at the lo
18 Sep 2017
- Focusing on further PQ912 development strategy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
- Focusing on further PQ912 development strategy
Vivoryon Therapeutics N.V. (VVY:AMS) | 0 0 0.0%
- Published:
18 Sep 2017 -
Author:
Dr Jonas Peciulis -
Pages:
4
Operating costs in H117 were largely in line with our expectations, while a one-off payment was a welcome resolution of Probiodrug’s long-outstanding potential tax liability. Following the overall positive Phase IIa data with PQ912 for Alzheimer’s disease (AD) released in June 2017, Probiodrug reiterated in its H117 report that all strategic options for further development are on the table. Depending on available funding, the company could initiate the next study looking at the lo